DA Davidson Maintains Buy on Cellebrite DI, Raises Price Target to $22

Benzinga Newsdesk www.benzinga.com Positive 78.1%

Neg 0% Neu 0% Pos 78.1%

DA Davidson analyst Rudy Kessinger maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and raises the price target from $20 to $22.